Comprehensive analysis of adverse events associated with onasemnogene abeparvovec (Zolgensma) in spinal muscular atrophy patients: insights from FAERS database
Onasemnogene Abeparvovec (Zolgensma) is a gene therapy for the treatment of Spinal Muscular Atrophy (SMA) with improved motor neuron function and the potential for a singular treatment. Information on its adverse drug reactions is mainly from clinical trials and real-world studies with extensive sam...
Saved in:
Main Authors: | Wenwen Zhang, Yizhen Yin, Dan Yang, Mengyuan Liu, Caixia Ye, Ruiling Yan, Ruiman Li |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2025-01-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2024.1475884/full |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Reviews of spinal muscular atrophy in Taiwan
by: Yung-Hsiu Lu, et al.
Published: (2024-12-01) -
Effect of nusinersen on pulmonary function in children with spinal muscular atrophy in the plateau region: A pilot study
by: Jicai Zhu, et al.
Published: (2025-01-01) -
Spinal muscular atrophy type 1 in the Caribbean: the first case report from the Dominican Republic
by: María Belén Martín-Sanz, et al.
Published: (2025-01-01) -
Maximal mouth opening in infants and toddlers with spinal muscular atrophy: a prospective controlled study
by: Jana Zang, et al.
Published: (2025-01-01) -
Rare coexistence of spinal muscular atrophy with membranous nephropathy – A clinical conundrum with management dilemma
by: Gerry G. Mathew, et al.
Published: (2024-12-01)